Navigation Links
GW Pharmaceuticals to Present at the 2013 Aegis Capital Healthcare Conference
Date:9/19/2013

LONDON, Sept. 20, 2013 /PRNewswire/ -- GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW") announced that Justin Gover, GW's Chief Executive Officer, is scheduled to present a general company update at the 2013 Aegis Capital Healthcare Conference in Las Vegas, NV on Friday, September 27, 2013, at 9:00 a.m. PT (12:00 p.m. ET).

About GW Pharmaceuticals plc
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 22 countries. Sativex is also in Phase 3 clinical development as a potential treatment of pain in people with advanced cancer. This Phase 3 program is intended to support the submission of a New Drug Application for Sativex in cancer pain with the U.S. Food and Drug Administration and in other markets around the world. GW has established a world leading position in the development of plant-derived cannabinoid therapeutics and has a deep pipeline of additional cannabinoid product candidates, including two distinct compounds, GWP42004 and GWP42003, in Phase 2 clinical development for Type 2 diabetes and ulcerative colitis, respectively, and GWP42006 in Phase 1 clinical development for the treatment of epilepsy. For further information, please visit www.gwpharm.com.


'/>"/>
SOURCE GW Pharmaceuticals plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Neurotech Pharmaceuticals Adds Ophthalmic Leaders to Advance Groundbreaking Sight-Saving Therapies
2. RXi Pharmaceuticals to Present at the 12th Annual BIO Investor Forum
3. Technical Study: Gilead Sciences Inc., Halozyme Therapeutics Inc., NPS Pharmaceuticals Inc., and InterMune Inc.
4. Life Cycle Management of Biopharmaceuticals, New Life Science Webinar Hosted by Xtalks
5. Inovio Pharmaceuticals to Hold Investor Conference Call to Discuss Partnership with Roche
6. Before the Bell Scans: Hologic Inc., St. Jude Medical Inc., ResMed Inc., and Navidea Biopharmaceuticals Inc.
7. EnduRx Pharmaceuticals to Present at 2013 Rocky Mountain Life Science Investor and Partnering Conference
8. EpiCept Announces Reverse Stock Split and Change of Corporate Name to Immune Pharmaceuticals Inc.
9. Intercept Pharmaceuticals Reports Second Quarter 2013 Financial Results
10. GW Pharmaceuticals to Present at the 33rd Annual Canaccord Genuity Growth Conference
11. James Mazzo Appointed Executive Chairman of Neurotech Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ("SQI" or the "Company") (TSX-V: SQD; OTCQX: SQIDF), today reported its financial ... September 30, 2016. ... , SQI is a ... and commercializes proprietary technologies and products for advanced multiplexed diagnostics. ... million more than tripling prior years revenue. ...
(Date:12/6/2016)... ... December 06, 2016 , ... Discovering new clues to natural ... with lasers what’s happening in our brains. And searching for keys to our immune ... research being honored with the 2017 Edith and Peter O’Donnell Awards by ...
(Date:12/6/2016)... ... December 06, 2016 , ... Clinical Supplies ... has acquired the assets of Theorem Clinical Research - Clinical Supplies ("TCS"). ... trial drug packaging, labeling, storage, reconciliation, and distribution for pharmaceutical trials across ...
(Date:12/6/2016)... WARSAW, Ind. , Dec. 6, 2016 ... (the "Company") today announced the pricing terms of ... up to $1.25 billion aggregate purchase price (excluding accrued ... applicable settlement date and excluding fees and expenses ... of the debt securities identified in the table ...
Breaking Biology Technology:
(Date:12/6/2016)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) (the "Company") ... million principal amount of its 1.414% senior unsecured notes due ... unsecured notes due 2026. The closing of ... to the satisfaction of customary closing conditions.  The notes will ... The Company intends to use the net proceeds from ...
(Date:12/2/2016)... , December 1, 2016 ... (Fingerprint, Voice), Future Technology (Iris Recognition System), Vehicle ... - Global Forecast to 2021", published by MarketsandMarkets, ... Million in 2016, and is projected to grow ... CAGR of 14.06%.      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
(Date:11/29/2016)... 29, 2016 BioDirection, a privately held medical ... the objective detection of concussion and other traumatic brain ... completed a meeting with the U.S. Food and Drug ... Pre-Submission Package. During the meeting company representatives reviewed plans ... precursor to commencement of a planned pilot trial. ...
Breaking Biology News(10 mins):